Physician profile
Stephine Kramer
NPI 1316083280
$2,323.61
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $364 · 2021: $618 · 2022: $589 · 2023: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.10 | 2019-2022 | |
| Hologic Sales and Service, LLC | $189.98 | 2019-2023 | Acessa Provu System |
| Allergan, INC. | $179.74 | 2019-2020 | |
| Myovant Sciences INC. | $150.56 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $135.23 | 2021-2023 | |
| Therapeuticsmd, INC. | $129.48 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.64 | 2019-2023 | |
| Gynesonics, INC. | $113.07 | 2022 | |
| Mylan Pharmaceuticals INC. | $77.04 | 2020-2022 | |
| Channel Medsystems, INC. | $73.33 | 2022 | |
| Ethicon US, LLC | $65.28 | 2019-2023 | Ethicon, Stratafix, Vistaseal |
| Daiichi Sankyo INC. | $64.37 | 2020-2021 | |
| Coopersurgical, INC. | $59.48 | 2019-2022 | |
| Agile Therapeutics, INC. | $52.50 | 2021 | |
| Organon LLC | $45.03 | 2022-2023 | Nexplanon |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $41.86 | 2021-2022 | |
| Smith+Nephew, INC. | $37.63 | 2021 | |
| Exeltis, USA INC. | $36.16 | 2021 | |
| Merck Sharp & Dohme LLC | $29.38 | 2019-2020 | |
| Lupin INC. | $25.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.24 | 2019 | |
| Roche Diagnostics Corporation | $24.08 | 2019 | |
| Sumitomo Pharma America, INC. | $22.51 | 2023 | Myfembree |
| Shield Therapeutics INC | $21.99 | 2023 | Accrufer |
| Boston Scientific Corporation | $21.34 | 2019 | |
| Covidien LP | $17.37 | 2019 | |
| Sage Therapeutics, LLC | $16.65 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $14.72 | 2023 | Vivjoa |
| Minerva Surgical, INC | $14.03 | 2019 | |
| Meditrina | $12.46 | 2022 | |
| Pfizer INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephine Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.